Tumormarkører ved epitelial ovariecancer

Morten H Sparholt; Estrid Høgdall; Claus K Høgdall; Morten H Sparholt; Estrid Høgdall; Claus K Høgdall

Tumormarkører ved epitelial ovariecancer

Translated title of the contribution: Tumour markers in epithelial ovarian cancer

Morten H Sparholt, Estrid Høgdall, Claus K Høgdall, Morten H Sparholt, Estrid Høgdall, Claus K Høgdall

Faculty of Health and Medical Sciences

2 Citations (Scopus)

Abstract

In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.

Translated title of the contribution	Tumour markers in epithelial ovarian cancer
Original language	Danish
Journal	Ugeskrift for læger
Volume	171
Issue number	48
Pages (from-to)	3505-9
Number of pages	5
ISSN	0041-5782
Publication status	Published - 23 Nov 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c8183fe068a111df928f000ea68e967b,

title = "Tumormark{\o}rer ved epitelial ovariecancer",

abstract = "In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23",

author = "Sparholt, {Morten H} and Estrid H{\o}gdall and H{\o}gdall, {Claus K} and Sparholt, {Morten H} and Estrid H{\o}gdall and H{\o}gdall, {Claus K}",

note = "Keywords: CA-125 Antigen; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Individualized Medicine; Mass Screening; Ovarian Neoplasms; Sensitivity and Specificity; Tumor Markers, Biological",

year = "2009",

month = nov,

day = "23",

language = "Dansk",

volume = "171",

pages = "3505--9",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "48",

}

TY - JOUR

T1 - Tumormarkører ved epitelial ovariecancer

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

N1 - Keywords: CA-125 Antigen; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Individualized Medicine; Mass Screening; Ovarian Neoplasms; Sensitivity and Specificity; Tumor Markers, Biological

PY - 2009/11/23

Y1 - 2009/11/23

N2 - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23

AB - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 171

SP - 3505

EP - 3509

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 48

ER -

Tumormarkører ved epitelial ovariecancer

Abstract

UN SDGs

Fingerprint

Cite this